BACKGROUND: High platelet counts are associated with an adverse effect on survival in various neoplastic entities. The prognostic relevance of preoperative platelet count in pancreatic cancer has not been clarified. METHODS: We performed a retrospective review of 205 patients with ductal adenocarcinoma who underwent surgical resection between 1990 and 2003. Demographic, surgical, and clinicopathologic variables were collected. A cutoff of 300,000/mul was used to define high platelet count. RESULTS: Of the 205 patients, 56 (27.4%) had a high platelet count, whereas 149 patients (72.6%) comprised the low platelet group. The overall median survival was 17 (2-178) months. The median survival of the high platelet group was 18 (2-137) months, and that of the low platelet group was 15 (2-178) months (p = 0.7). On multivariate analysis, lymph node metastasis, vascular invasion, positive margins, and CA 19-9 > 200 U/ml were all significantly associated with poor survival. CONCLUSIONS: There is no evidence to support preoperative platelet count as either an adverse or favorable prognostic factor in pancreatic ductal adenocarcinoma. Use of 5-year actual survival data confirms that lymph node metastases, positive margins, vascular invasion, and CA 19-9 are predictors of poor survival in resected pancreatic cancer.
BACKGROUND: High platelet counts are associated with an adverse effect on survival in various neoplastic entities. The prognostic relevance of preoperative platelet count in pancreatic cancer has not been clarified. METHODS: We performed a retrospective review of 205 patients with ductal adenocarcinoma who underwent surgical resection between 1990 and 2003. Demographic, surgical, and clinicopathologic variables were collected. A cutoff of 300,000/mul was used to define high platelet count. RESULTS: Of the 205 patients, 56 (27.4%) had a high platelet count, whereas 149 patients (72.6%) comprised the low platelet group. The overall median survival was 17 (2-178) months. The median survival of the high platelet group was 18 (2-137) months, and that of the low platelet group was 15 (2-178) months (p = 0.7). On multivariate analysis, lymph node metastasis, vascular invasion, positive margins, and CA 19-9 > 200 U/ml were all significantly associated with poor survival. CONCLUSIONS: There is no evidence to support preoperative platelet count as either an adverse or favorable prognostic factor in pancreatic ductal adenocarcinoma. Use of 5-year actual survival data confirms that lymph node metastases, positive margins, vascular invasion, and CA 19-9 are predictors of poor survival in resected pancreatic cancer.
Authors: K F D Kuhlmann; S M M de Castro; J G Wesseling; F J W ten Kate; G J A Offerhaus; O R C Busch; T M van Gulik; H Obertop; D J Gouma Journal: Eur J Cancer Date: 2004-03 Impact factor: 9.162
Authors: Revathi Suppiah; Philip E Shaheen; Paul Elson; Seema A Misbah; Laura Wood; Robert J Motzer; Slyvie Negrier; Steven W Andresen; Ronald M Bukowski Journal: Cancer Date: 2006-10-15 Impact factor: 6.860
Authors: Andrew J Li; Alison C Madden; Ilana Cass; Ronald S Leuchter; Leo D Lagasse; Beth Y Karlan Journal: Gynecol Oncol Date: 2004-01 Impact factor: 5.482
Authors: Andreas Nather; Klaus Mayerhofer; Christoph Grimm; Lukas Hefler; Sepp Leodolter; Andreas Obermair; Elmar A Joura Journal: Anticancer Res Date: 2003 May-Jun Impact factor: 2.480
Authors: Ryoko Suzuki; Steven H Lin; Xiong Wei; Pamela K Allen; James W Welsh; Lauren A Byers; Ritsuko Komaki Journal: Radiother Oncol Date: 2018-02-02 Impact factor: 6.280
Authors: Elani Streja; Csaba P Kovesdy; Sander Greenland; Joel D Kopple; Charles J McAllister; Allen R Nissenson; Kamyar Kalantar-Zadeh Journal: Am J Kidney Dis Date: 2008-08-29 Impact factor: 8.860
Authors: Patrick B Schwartz; George Poultsides; Kevin Roggin; John H Howard; Ryan C Fields; Callisia N Clarke; Konstantinos Votanopoulos; Kenneth Cardona; Emily R Winslow Journal: J Surg Res Date: 2020-03-12 Impact factor: 2.192